Search

Your search keyword '"Valik D"' showing total 126 results
Start Over Author "Valik D"
126 results on '"Valik D"'

2. 1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity

Author

Obermannova, R., primary, Demlova, R., additional, Selingerova, I., additional, Doubek, M., additional, Okrouhlicova, D., additional, Mlnarikova, M., additional, Pilatova, K., additional, Nevrlka, J., additional, Lejdarova, H., additional, Weinbergerova, B., additional, Cermakova, Z., additional, Valik, D., additional, Mayer, J., additional, Kiss, I., additional, and Zdrazilova-Dubska, L., additional

Published
2021
Full Text
View/download PDF

8. Customized or randomized trials for relapsed refractory pediatric Burkitt lymphomas? A retrospective analysis of two clinical cases with comprehensive molecular profiling: Possible explanation for different treatment outcomes after similar targeted therapies

Author

Polaskova, K., primary, Martincekova, A., additional, Krenova, Z., additional, Valik, D., additional, Noskova, H., additional, Slaby, O., additional, Kanderova, V., additional, Hrusak, O., additional, Klement, G.L., additional, Neradil, J., additional, Veselska, R., additional, and Sterba, J., additional

Published
2018
Full Text
View/download PDF

11. Abstracts from the 4th ImmunoTherapy of Cancer Conference

Author

Ženka, J., primary, Caisová, V., additional, Uher, O., additional, Nedbalová, P., additional, Kvardová, K., additional, Masáková, K., additional, Krejčová, G., additional, Paďouková, L., additional, Jochmanová, I., additional, Wolf, K. I., additional, Chmelař, J., additional, Kopecký, J., additional, Loumagne, L., additional, Mestadier, J., additional, D’agostino, S., additional, Rohaut, A., additional, Ruffin, Y., additional, Croize, V., additional, Lemaître, O., additional, Sidhu, S. S., additional, Althammer, S., additional, Steele, K., additional, Rebelatto, M., additional, Tan, T., additional, Wiestler, T., additional, Spitzmueller, A., additional, Korn, R., additional, Schmidt, G., additional, Higgs, B., additional, Li, X., additional, Shi, L., additional, Jin, X., additional, Ranade, K., additional, Koeck, S., additional, Amann, A., additional, Gamerith, G., additional, Zwierzina, M., additional, Lorenz, E., additional, Zwierzina, H., additional, Kern, J., additional, Riva, M., additional, Baert, T., additional, Coosemans, A., additional, Giovannoni, R., additional, Radaelli, E., additional, Gsell, W., additional, Himmelreich, U., additional, Van Ranst, M., additional, Xing, F., additional, Qian, W., additional, Dong, C., additional, Xu, X., additional, Guo, S., additional, Shi, Q., additional, Quandt, D., additional, Seliger, B., additional, Plett, C., additional, Amberger, D. C., additional, Rabe, A., additional, Deen, D., additional, Stankova, Z., additional, Hirn, A., additional, Vokac, Y., additional, Werner, J., additional, Krämer, D., additional, Rank, A., additional, Schmid, C., additional, Schmetzer, H., additional, Guerin, M., additional, Weiss, J. M., additional, Regnier, F., additional, Renault, G., additional, Vimeux, L., additional, Peranzoni, E., additional, Feuillet, V., additional, Thoreau, M., additional, Guilbert, T., additional, Trautmann, A., additional, Bercovici, N., additional, Doraneh-Gard, F., additional, Boeck, C. L., additional, Gunsilius, C., additional, Kugler, C., additional, Schmohl, J., additional, Kraemer, D., additional, Ismann, B., additional, Schmetzer, H. M., additional, Markota, A., additional, Ochs, C., additional, May, P., additional, Gottschlich, A., additional, Gosálvez, J. Suárez, additional, Karches, C., additional, Wenk, D., additional, Endres, S., additional, Kobold, S., additional, Hilmenyuk, T., additional, Klar, R., additional, Jaschinski, F., additional, Augustin, F., additional, Manzl, C., additional, Hoflehner, E., additional, Moser, P., additional, Zelger, B., additional, Köck, S., additional, Schäfer, G., additional, Öfner, D., additional, Maier, H., additional, Sopper, S., additional, Prado-Garcia, H., additional, Romero-Garcia, S., additional, Sandoval-Martínez, R., additional, Puerto-Aquino, A., additional, Lopez-Gonzalez, J., additional, Rumbo-Nava, U., additional, Van Hoylandt, A., additional, Busschaert, P., additional, Vergote, I., additional, Laengle, J., additional, Pilatova, K., additional, Budinska, E., additional, Bencsikova, B., additional, Sefr, R., additional, Nenutil, R., additional, Brychtova, V., additional, Fedorova, L., additional, Hanakova, B., additional, Zdrazilova-Dubska, L., additional, Allen, Chris, additional, Ku, Yuan-Chieh, additional, Tom, Warren, additional, Sun, Yongming, additional, Pankov, Alex, additional, Looney, Tim, additional, Hyland, Fiona, additional, Au-Young, Janice, additional, Mongan, Ann, additional, Becker, A., additional, Tan, J. B. L., additional, Chen, A., additional, Lawson, K., additional, Lindsey, E., additional, Powers, J. P., additional, Walters, M., additional, Schindler, U., additional, Young, S., additional, Jaen, J. C., additional, Yin, S., additional, Chen, Y., additional, Gullo, I., additional, Gonçalves, G., additional, Pinto, M. L., additional, Athelogou, M., additional, Almeida, G., additional, Huss, R., additional, Oliveira, C., additional, Carneiro, F., additional, Merz, C., additional, Sykora, J., additional, Hermann, K., additional, Hussong, R., additional, Richards, D. M., additional, Fricke, H., additional, Hill, O., additional, Gieffers, C., additional, Pinho, M. P., additional, Barbuto, J. A. M., additional, McArdle, S. E., additional, Foulds, G., additional, Vadakekolathu, J. N., additional, Abdel-Fatah, T. M. A., additional, Johnson, C., additional, Hood, S., additional, Moseley, P., additional, Rees, R. C., additional, Chan, S. Y. T., additional, Pockley, A. G., additional, Rutella, S., additional, Geppert, C., additional, Hartmann, A., additional, Kumar, K. Senthil, additional, Gokilavani, M., additional, Wang, S., additional, Redondo-Müller, M., additional, Heinonen, K., additional, Marschall, V., additional, Thiemann, M., additional, Zhang, L., additional, Mao, B., additional, Jin, Y., additional, Zhai, G., additional, Li, Z., additional, Wang, Z., additional, An, X., additional, Qiao, M., additional, Zhang, J., additional, Weber, J., additional, Kluger, H., additional, Halaban, R., additional, Sznol, M., additional, Roder, H., additional, Roder, J., additional, Grigorieva, J., additional, Asmellash, S., additional, Meyer, K., additional, Steingrimsson, A., additional, Blackmon, S., additional, Sullivan, R., additional, Sutanto, W., additional, Guenther, T., additional, Schuster, F., additional, Salih, H., additional, Babor, F., additional, Borkhardt, A., additional, Kim, Y., additional, Oh, I., additional, Park, C., additional, Ahn, S., additional, Na, K., additional, Song, S., additional, Choi, Y., additional, Poprach, A., additional, Lakomy, R., additional, Selingerova, I., additional, Demlova, R., additional, Kozakova, S., additional, Valik, D., additional, Petrakova, K., additional, Vyzula, R., additional, Aguilar-Cazares, D., additional, Galicia-Velasco, M., additional, Camacho-Mendoza, C., additional, Islas-Vazquez, L., additional, Chavez-Dominguez, R., additional, Gonzalez-Gonzalez, C., additional, Lopez-Gonzalez, J. S., additional, Yang, S., additional, Moynihan, K. D., additional, Noh, M., additional, Bekdemir, A., additional, Stellacci, F., additional, Irvine, D. J., additional, Volz, B., additional, Kapp, K., additional, Oswald, D., additional, Wittig, B., additional, Schmidt, M., additional, Kleef, R., additional, Bohdjalian, A., additional, McKee, D., additional, Moss, R. W., additional, Saeed, Mesha, additional, Zalba, Sara, additional, Debets, Reno, additional, ten Hagen, Timo L. M., additional, Javed, S., additional, Becher, J., additional, Koch-Nolte, F., additional, Haag, F., additional, Gordon, E. M., additional, Sankhala, K. K., additional, Stumpf, N., additional, Tseng, W., additional, Chawla, S. P., additional, Suárez, N. González, additional, Báez, G. Bergado, additional, Rodríguez, M. Cruz, additional, Pérez, A. Gutierrez, additional, García, L. Chao, additional, Fernández, D. Hernández, additional, Pous, J. Raymond, additional, Ramírez, B. Sánchez, additional, Jacoberger-Foissac, C., additional, Saliba, H., additional, Seguin, C., additional, Brion, A., additional, Frisch, B., additional, Fournel, S., additional, Heurtault, B., additional, Otterhaug, T., additional, Håkerud, M., additional, Nedberg, A., additional, Edwards, V., additional, Selbo, P., additional, Høgset, A., additional, Jaitly, T., additional, Dörrie, J., additional, Schaft, N., additional, Gross, S., additional, Schuler-Thurner, B., additional, Gupta, S., additional, Taher, L., additional, Schuler, G., additional, Vera, J., additional, Rataj, F., additional, Kraus, F., additional, Grassmann, S., additional, Chaloupka, M., additional, Lesch, S., additional, Heise, C., additional, Cadilha, B. M. Loureiro, additional, and Dorman, K., additional

Published
2017
Full Text
View/download PDF

15. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma

Author

Staufer, K, Gao, CF, Valik, D, Greplova, K, Muller, P, Nenutil, R, Mikulits, W, Man, K, Trauner, M, Starlinger, P, Fang, M, Reichl, P, Yu, J, Gruenberger, T, Dooley, S, Shen, J, and Brostjan, C

Subjects
Liver Cirrhosis, Male, Carcinoma, Hepatocellular, Liver Neoplasms, Receptor Protein-Tyrosine Kinases, Enzyme-Linked Immunosorbent Assay, Hep G2 Cells, Kaplan-Meier Estimate, Middle Aged, Axl Receptor Tyrosine Kinase, digestive system diseases, Article, Diagnosis, Differential, Early Diagnosis, ROC Curve, Solubility, Cell Line, Tumor, Proto-Oncogene Proteins, Biomarkers, Tumor, Humans, Female, alpha-Fetoproteins, neoplasms, Neoplasm Staging
Abstract

If diagnosed at early stages, patients with hepatocellular carcinoma (HCC) can receive curative therapies, whereas therapeutic options at later stages are very limited. Here, we addressed the potential of soluble Axl (sAxl) as a biomarker of early HCC by analyzing levels of sAxl in 311 HCC and 237 control serum samples from centers in Europe and China. Serum concentrations of sAxl were significantly increased in HCC (18.575 ng/mL) as compared to healthy (13.388 ng/mL) or cirrhotic (12.169 ng/mL) controls. Receiver operating characteristic curve analysis of sAxl in very early stage HCC patients (BCLC 0) showed an area under the curve (AUC) of 0.848, with a sensitivity of 76.9% and a specificity of 69.2%. α-Fetoprotein (AFP)-negative HCC patients displayed an AUC of 0.803, with sensitivity and specificity of 73% and 70.8%. Combination of sAxl and AFP improved diagnostic accuracy to 0.936 in very early HCC patients and to 0.937 in all HCC. Differential diagnosis of very early HCC versus liver cirrhosis showed a combined performance for sAxl and AFP of 0.901 with a sensitivity of 88.5% and a specificity of 76.7%. Furthermore, sAxl levels failed to be elevated in primary ovarian, colorectal and breast carcinomas as well as in secondary hepatic malignancies derived from colon. In summary, sAxl outperforms AFP in detecting very early HCC as compared to healthy or cirrhotic controls and shows high diagnostic accuracy for AFP-negative patients. sAxl is specific for HCC and suggested as a biomarker for routine clinical use.

Published
2015

18. P0346 : Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma

Author

Reichl, P., primary, Fang, M., additional, Starlinger, P., additional, Staufer, K., additional, Nenutil, R., additional, Muller, P., additional, Greplova, K., additional, Valik, D., additional, Dooley, S., additional, Brostjan, C., additional, Gruenberger, T., additional, Shen, J., additional, Man, K., additional, Trauner, M., additional, Yu, J., additional, Gao, C.F., additional, and Mikulits, W., additional

Published
2015
Full Text
View/download PDF

22. Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience

Author

Zapletalova, D., primary, André, N., additional, Deak, L., additional, Kyr, M., additional, Bajciova, V., additional, Mudry, P., additional, Dubska, L., additional, Demlova, R., additional, Pavelka, Z., additional, Zitterbart, K., additional, Skotakova, J., additional, Husek, K., additional, Martincekova, A., additional, Mazanek, P., additional, Kepak, T., additional, Doubek, M., additional, Kutnikova, L., additional, Valik, D., additional, and Sterba, J., additional

Published
2012
Full Text
View/download PDF

27. Serum tissue polypeptide-specific antigen (TPS): what is its diagnostic value?

Author

Valik, D and Nekulova, M

Subjects
Male, Analysis of Variance, Infant, Newborn, Infant, Wilms Tumor, Kidney Neoplasms, Neoplasm Proteins, Neuroblastoma, ROC Curve, Child, Preschool, Humans, Female, Tissue Polypeptide Antigen, Letters to the Editor, Child
Abstract

Although tissue polypeptide-specific antigen (TPS) has been described as a potentially useful serum marker of tumour activity in adult epithelial tumours, few data are available for childhood malignancies. Neuroblastomas and Wilms' tumours are the commonest types of solid malignancies found in the retroperitoneum of children. At this time, a widely used marker for Wilms' tumour is not available. Using an enzyme-linked immunosorbent assay (ELISA) kit, serum TPS levels in 23 children with neuroblastomas, nine with Wilms' tumours and 22 with benign tumours were evaluated to test the usefulness of the marker in identifying malignancies. Compared with healthy children (n = 110), the preoperative least-square means (LSM) of serum TPS were considerably elevated in both neuroblastoma (LSM = 209 U l(-1)) and Wilms' tumour (LSM = 235 U l(-1)), whereas values in benign tumours were only slightly elevated. Although the Wilms' tumours were associated with higher preoperative serum TPS levels, there was no statistically significant difference compared with neuroblastomas. Receiver operating characteristic analysis (ROC curves) showed a high sensitivity and specificity for both malignancies. Successful treatment resulted in decrease in TPS serum values. Serum TPS measurements in children presenting with abdominal masses can help in diagnosing the two commonest extracranial solid malignancies of childhood. Furthermore, TPS could acquire a pivotal role in monitoring therapy.

Published
2000

38. NKT-like cells are expanded in solid tumour patients

Author

Lenka Zdrazilova-Dubska, Valik D, Budinska E, Frgala T, Bacikova L, and Demlova R

Subjects
CD3 Complex, Neoplasms, Humans, Natural Killer T-Cells, Breast Neoplasms, Lymphocyte Count, Flow Cytometry, CD56 Antigen, Lymphocyte Subsets, Immunophenotyping
Abstract

CD3+ CD56+ NKT-like cells have been shown to produce substantial amounts of pro-inflammatory cytokines and to mediate lysis of malignant cells. Using flow cytometry, we evaluated the absolute NKT-like cell count in peripheral blood from individuals in a reference population and the median number was 0.085 x 10(9)/l. The average number of NKT-like cells in patients with disseminated cancer was 2.65 fold higher than in the reference population. The number of CD3+ CD56+ cells in solid tumour patients who achieved complete remission was comparable to the reference population. In breast cancer patients with initially (prior to therapy) increased number of NKT-like cells, we observed a trend toward longer disease-free survival. Thus we conclude that CD3+ CD56+ NKT-like cells have potential to suppress tumour evasion and are expanded in peripheral blood of some epithelial tumour patients.

40. Abstracts from the 4th ImmunoTherapy of Cancer Conference

Author

Ženka, J., Caisová, V., Uher, O., Nedbalová, P., Kvardová, K., Masáková, K., Krejčová, G., Paďouková, L., Jochmanová, I., Wolf, K. I., Chmelař, J., Kopecký, J., Loumagne, L., Mestadier, J., D’agostino, S., Rohaut, A., Ruffin, Y., Croize, V., Lemaître, O., Sidhu, S. S., Althammer, S., Steele, K., Rebelatto, M., Tan, T., Wiestler, T., Spitzmueller, A., Korn, R., Schmidt, G., Higgs, B., Li, X., Shi, L., Jin, X., Ranade, K., Koeck, S., Amann, A., Gamerith, G., Zwierzina, M., Lorenz, E., Zwierzina, H., Kern, J., Riva, M., Baert, T., Coosemans, A., Giovannoni, R., Radaelli, E., Gsell, W., Himmelreich, U., Van Ranst, M., Xing, F., Qian, W., Dong, C., Xu, X., Guo, S., Shi, Q., Quandt, D., Seliger, B., Plett, C., Amberger, D. C., Rabe, A., Deen, D., Stankova, Z., Hirn, A., Vokac, Y., Werner, J., Krämer, D., Rank, A., Schmid, C., Schmetzer, H., Guerin, M., Weiss, J. M., Regnier, F., Renault, G., Vimeux, L., Peranzoni, E., Feuillet, V., Thoreau, M., Guilbert, T., Trautmann, A., Bercovici, N., Doraneh-Gard, F., Boeck, C. L., Gunsilius, C., Kugler, C., Schmohl, J., Kraemer, D., Ismann, B., Schmetzer, H. M., Markota, A., Ochs, C., May, P., Gottschlich, A., Gosálvez, J. Suárez, Karches, C., Wenk, D., Endres, S., Kobold, S., Hilmenyuk, T., Klar, R., Jaschinski, F., Augustin, F., Manzl, C., Hoflehner, E., Moser, P., Zelger, B., Köck, S., Schäfer, G., Öfner, D., Maier, H., Sopper, S., Prado-Garcia, H., Romero-Garcia, S., Sandoval-Martínez, R., Puerto-Aquino, A., Lopez-Gonzalez, J., Rumbo-Nava, U., Van Hoylandt, A., Busschaert, P., Vergote, I., Laengle, J., Pilatova, K., Budinska, E., Bencsikova, B., Sefr, R., Nenutil, R., Brychtova, V., Fedorova, L., Hanakova, B., Zdrazilova-Dubska, L., Allen, Chris, Ku, Yuan-Chieh, Tom, Warren, Sun, Yongming, Pankov, Alex, Looney, Tim, Hyland, Fiona, Au-Young, Janice, Mongan, Ann, Becker, A., Tan, J. B. L., Chen, A., Lawson, K., Lindsey, E., Powers, J. P., Walters, M., Schindler, U., Young, S., Jaen, J. C., Yin, S., Chen, Y., Gullo, I., Gonçalves, G., Pinto, M. L., Athelogou, M., Almeida, G., Huss, R., Oliveira, C., Carneiro, F., Merz, C., Sykora, J., Hermann, K., Hussong, R., Richards, D. M., Fricke, H., Hill, O., Gieffers, C., Pinho, M. P., Barbuto, J. A. M., McArdle, S. E., Foulds, G., Vadakekolathu, J. N., Abdel-Fatah, T. M. A., Johnson, C., Hood, S., Moseley, P., Rees, R. C., Chan, S. Y. T., Pockley, A. G., Rutella, S., Geppert, C., Hartmann, A., Kumar, K. Senthil, Gokilavani, M., Wang, S., Redondo-Müller, M., Heinonen, K., Marschall, V., Thiemann, M., Zhang, L., Mao, B., Jin, Y., Zhai, G., Li, Z., Wang, Z., An, X., Qiao, M., Zhang, J., Weber, J., Kluger, H., Halaban, R., Sznol, M., Roder, H., Roder, J., Grigorieva, J., Asmellash, S., Meyer, K., Steingrimsson, A., Blackmon, S., Sullivan, R., Sutanto, W., Guenther, T., Schuster, F., Salih, H., Babor, F., Borkhardt, A., Kim, Y., Oh, I., Park, C., Ahn, S., Na, K., Song, S., Choi, Y., Poprach, A., Lakomy, R., Selingerova, I., Demlova, R., Kozakova, S., Valik, D., Petrakova, K., Vyzula, R., Aguilar-Cazares, D., Galicia-Velasco, M., Camacho-Mendoza, C., Islas-Vazquez, L., Chavez-Dominguez, R., Gonzalez-Gonzalez, C., Lopez-Gonzalez, J. S., Yang, S., Moynihan, K. D., Noh, M., Bekdemir, A., Stellacci, F., Irvine, D. J., Volz, B., Kapp, K., Oswald, D., Wittig, B., Schmidt, M., Kleef, R., Bohdjalian, A., McKee, D., Moss, R. W., Saeed, Mesha, Zalba, Sara, Debets, Reno, ten Hagen, Timo L. M., Javed, S., Becher, J., Koch-Nolte, F., Haag, F., Gordon, E. M., Sankhala, K. K., Stumpf, N., Tseng, W., Chawla, S. P., Suárez, N. González, Báez, G. Bergado, Rodríguez, M. Cruz, Pérez, A. Gutierrez, García, L. Chao, Fernández, D. Hernández, Pous, J. Raymond, Ramírez, B. Sánchez, Jacoberger-Foissac, C., Saliba, H., Seguin, C., Brion, A., Frisch, B., Fournel, S., Heurtault, B., Otterhaug, T., Håkerud, M., Nedberg, A., Edwards, V., Selbo, P., Høgset, A., Jaitly, T., Dörrie, J., Schaft, N., Gross, S., Schuler-Thurner, B., Gupta, S., Taher, L., Schuler, G., Vera, J., Rataj, F., Kraus, F., Grassmann, S., Chaloupka, M., Lesch, S., Heise, C., Cadilha, B. M. Loureiro, and Dorman, K.

Subjects
Meeting Abstracts
Full Text
View/download PDF

44. Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients.

Author

Kyr M, Mudry P, Polaskova K, Dubska LZ, Demlova R, Kubatova J, Hlavackova E, Pilatova KC, Mazanek P, Vejmelkova K, Dusek V, Tinka P, Balaz M, Merta T, Kuttnerova Z, Turekova T, Pavelka Z, Pokorna P, Palova H, Mlnarikova M, Jezova M, Kellnerova R, Kozakova S, Slaby O, Valik D, and Sterba J

Subjects
Humans, Male, Female, Child, Combined Modality Therapy, Child, Preschool, Adolescent, Administration, Metronomic, Immunotherapy methods, Vinblastine administration & dosage, Vinblastine therapeutic use, Infant, Immune Checkpoint Inhibitors therapeutic use, Follow-Up Studies, Dendritic Cells immunology, Cancer Vaccines administration & dosage, Cancer Vaccines therapeutic use, Neoplasms mortality, Neoplasms immunology, Neoplasms therapy, Neoplasms drug therapy, Precision Medicine methods, Cyclophosphamide therapeutic use, Cyclophosphamide administration & dosage
Abstract

A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high-risk solid tumors using the N-of-1 approach in real-world scenario. A total of 160 evaluable events occurred in 48 patients during the 4-year follow-up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check-point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents., (© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)

Published
2024
Full Text
View/download PDF

45. Emergency medicine pharmacotherapy compromises accuracy of plasma creatinine determination by enzyme-based methods: real-world clinical evidence and implications for clinical practice.

Author

Demlova R, Kozakova S, Rihacek M, Buckova D, Horska K, Wiewiorka O, Boucek L, Selingerova I, Podborska M, Korberova A, Mikuskova A, Starha J, Benovska M, Radina M, Richter M, Zdrazilova Dubska L, and Valik D

Abstract

Background: Assessment of kidney function in emergency settings is essential across all medical subspecialties. Daily assessment of patient creatinine results from emergency medical services showed that some deviated from expected values, implying drug-related interference., Methods: Real-time clinical evaluation of an enzyme method (Roche CREP2) in comparison with the Jaffé gen. 2 method (Roche CREJ2) was performed. During the period of December 2022 and January 2023, we analyzed 8,498 patient samples, where 5,524 were heavily medicated STAT patient specimens, 500 were pediatric specimens, and 2,474 were from a distant general population in a different region using the same methods., Results: In 109 out of 5,524 hospital specimens (1.97%, p  < 0.001), the CREP2 value was apparently (25% or more) lower than CREJ2. Suspect interfering medication was found in a sample of 43 out of 46 reviewed patients where medication data were available. This phenomenon was not observed in the general population., Conclusion: In a polymedicated urgent care hospital population, a creatinine enzyme method produces unreliable results, apparently due to multiple drug-related interferences., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Demlova, Kozakova, Rihacek, Buckova, Horska, Wiewiorka, Boucek, Selingerova, Podborska, Korberova, Mikuskova, Starha, Benovska, Radina, Richter, Zdrazilova Dubska and Valik.)

Published
2024
Full Text
View/download PDF

46. Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors.

Author

Vejmelkova K, Pokorna P, Noskova K, Faustmannova A, Drabova K, Pavelka Z, Bajciova V, Broz M, Tinka P, Jezova M, Palova H, Kren L, Valik D, Slaby O, and Sterba J

Subjects
Humans, Child, Female, Infant, Child, Preschool, Neoplasm Recurrence, Local drug therapy, SMARCB1 Protein, DNA Helicases, Nuclear Proteins, Transcription Factors, Rhabdoid Tumor drug therapy, Rhabdoid Tumor pathology, Teratoma pathology, Central Nervous System Neoplasms pathology
Abstract

Rhabdoid tumors are aggressive tumors that may arise in the kidney, soft tissue, central nervous system, or other organs. They are defined by SMARCB1 (INI1) or SMARCA4 alterations. Often, very young children are affected, and the prognosis is dismal. Four patients with primary atypical teratoid rhabdoid tumor (AT/RT, a rhabdoid tumor in the central nervous system) were treated by resection and high dose chemotherapy. Tazemetostat was introduced after completion of chemotherapy. Three patients have achieved an event free survival of 32, 34, and 30 months respectively. One progressed and died. His overall survival was 20 months. One patient was treated for a relapsed atypical teratoid rhabdoid tumor. The treatment combined metronomic therapy, radiotherapy, tazemetostat and immunotherapy. This patient died of disease progression, with an overall survival of 37 months. One patient was treated for a rhabdoid tumor of the ovary. Tazemetostat was given as maintenance after resection, chemotherapy, and radiotherapy, concomitantly with immunotherapy. Her event free survival is 44 months. Only approximately 40% of patients with rhabdoid tumors achieve long-term survival. Nearly all relapses occur within two years from diagnosis. The event free survival of four of the six patients in our cohort has exceeded this timepoint. Tazemetostat has been mostly tested as a single agent in the relapsed setting. We present promising results when applied as maintenance or add on in the first line treatment., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

47. Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future.

Author

Rihackova E, Rihacek M, Vyskocilova M, Valik D, and Elbl L

Abstract

Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2023 Rihackova, Rihacek, Vyskocilova Valik and Elbl.)

Published
2023
Full Text
View/download PDF

48. Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients.

Author

Rihacek M, Selingerova I, Kocak I, Kocakova I, Rihackova E, Valik D, and Sterba J

Subjects
Adult, Child, Erythrocyte Indices, Humans, Indoles adverse effects, Pyrroles adverse effects, Retrospective Studies, Sunitinib pharmacology, Sunitinib therapeutic use, Antineoplastic Agents adverse effects, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell pathology, Kidney Neoplasms drug therapy, Kidney Neoplasms pathology
Abstract

Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an "off-label" option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, p = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course.

Published
2022
Full Text
View/download PDF

49. Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.

Author

Pokorna P, Lakka Klement G, Vasikova A, Kanderova V, Jezova M, Noskova K, Mudry P, Kyr M, Merta T, Bajciova V, Krenova Z, Palova H, Valik D, Zdrazilova Dubska L, Slaby O, and Sterba J

Subjects
Aminopyridines, Humans, Lactams, Lactams, Macrocyclic, Neoplasm, Residual, Pyrazoles therapeutic use, Lymphoma, Large-Cell, Anaplastic drug therapy
Abstract

Competing Interests: Giannoula Lakka KlementEmployment: CSTS Health Care Inc, Hessian LabsLeadership: CSTS Health Care IncStock and Other Ownership Interests: CSTS Health Care Inc, Hessian LabsConsulting or Advisory Role: Ipsen Lenka Zdrazilova DubskaHonoraria: Roche Ondrej SlabyHonoraria: Roche, Bristol Myers SquibbConsulting or Advisory Role: Roche, Bristol Myers Squibb Jaroslav SterbaResearch Funding: Roche/Genentech (Inst)Travel, Accommodations, Expenses: BMSNo other potential conflicts of interest were reported.

Published
2022
Full Text
View/download PDF

50. The Clinical Significance of DJ1 and L1CAM Serum Level Monitoring in Patients with Endometrial Cancer.

Author

Bednarikova M, Vinklerova P, Gottwaldova J, Ovesna P, Hausnerova J, Minar L, Felsinger M, Valik D, Cermakova Z, and Weinberger V

Abstract

Circulating tumor markers are not routinely used in patients with endometrial cancer (EC). This pilot study evaluated the role of monitoring new biomarkers DJ1 and L1CAM, in correlation with CA125 and HE4, for the effects of anticancer treatment and preoperative management in EC patients. Serial serum levels of DJ1, L1CAM, CA125 and HE4 were collected in 65 enrolled patients. Serum DJ1, L1CAM, CA125 and HE4 levels were significantly higher at the time of diagnosis compared to those measured during follow-up (FU). In patients with recurrent disease, serum DJ1, CA125 and HE4 levels were significantly higher at the time of recurrence compared to levels in disease-free patients. Serum L1CAM levels were also higher in patients with recurrence but without reaching statistical significance. While DJ1 levels were not affected by any of the observed patient-related characteristics, L1CAM levels were significantly higher in patients with age ≥60 years who were overweight. At the time of EC diagnosis, DJ1 and L1CAM serum levels did not correlate with stage, histological type or risk of recurrence. This is a preliminary description of the potential of serial DJ1 and L1CAM serum level measurement for monitoring the effects of treatment in EC patients.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results